INVESTMENTS - Additional Information (Details) - USD ($) $ in Millions |
1 Months Ended | 6 Months Ended |
|---|---|---|
Jan. 31, 2026 |
Jun. 30, 2026 |
|
| Series C Investment | ||
| Debt and Equity Securities, FV-NI [Line Items] | ||
| Net gain | $ 0.3 | |
| TJ Biopharma | ||
| Debt and Equity Securities, FV-NI [Line Items] | ||
| Ownership interest | 9.00% | |
| Total consideration | $ 13.2 | |
| TJ Biopharma | Series C Investment | ||
| Debt and Equity Securities, FV-NI [Line Items] | ||
| Ownership interest | 3.20% |
| X | ||||||||||
- Definition Percentage of ownership interest. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|